Cytological findings of ROS1‐rearranged lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Diagnostic Cytopathology"
DOI: 10.1002/dc.23845
Abstract: ROS1‐rearranged lung adenocarcinoma has been recently identified. We report a case of ROS1‐rearranged lung adenocarcinoma with special emphasis on cytological findings. Here, we report a case of young woman with ROS1‐rearranged lung adenocarcinoma diagnosed by… read more here.
Keywords: lung adenocarcinoma; cytological findings; rearranged lung; ros1 rearranged ... See more keywords
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.03.019
Abstract: INTRODUCTION ROS1-rearranged non-small cell lung cancer (NSCLC) has demonstrated promising response to lorlatinib; however, no targeted therapy is available after failure of lorlatinib and information on acquired resistance mechanisms mediating lorlatinib resistance among ROS1-rearranged NSCLC… read more here.
Keywords: lorlatinib resistance; ros1; resistance; ros1 g2032 ... See more keywords
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz131
Abstract: Abstract Background In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC). Here, we present updated antitumor activity, overall survival (OS) and safety data… read more here.
Keywords: advanced non; profile 1001; crizotinib; non small ... See more keywords
A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
Sign Up to like & getrecommendations! Published in 2020 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13496
Abstract: Reports of crizotinib‐induced pleural effusion in non‐small cell lung cancer (NSCLC) are limited. A 35‐year‐old Japanese woman was diagnosed with ROS1‐rearranged lung adenocarcinoma (primary left lower lobe, cT4N3M1c). Crizotinib was administered as first‐line therapy, and… read more here.
Keywords: lung adenocarcinoma; crizotinib; pleural effusion; effusion ... See more keywords
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2021 at "BMC Medicine"
DOI: 10.1186/s12916-021-02082-6
Abstract: ROS1-rearranged lung cancers benefit from first-line crizotinib therapy; however, clinical and molecular factors that could affect crizotinib efficacy in ROS1-rearranged lung cancers are not yet well-elucidated. Our retrospective study aimed to compare the efficacy of… read more here.
Keywords: first line; line crizotinib; ros1 rearranged; line ... See more keywords
Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy
Sign Up to like & getrecommendations! Published in 2019 at "Internal Medicine"
DOI: 10.2169/internalmedicine.1982-18
Abstract: Hypertrophic pulmonary osteoarthropathy (HPO) is a paraneoplastic syndrome characterized by digital clubbing, arthritis, and periostitis. Tumor removal usually leads to the resolution of these symptoms. We herein report the efficacy of crizotinib treatment for treating… read more here.
Keywords: rearranged lung; treatment; crizotinib; ros1 rearranged ... See more keywords
Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.645224
Abstract: Background Although C-ros oncogene 1 (ROS1) targeted therapies have demonstrated remarkable efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC), patients inevitably develop resistance to ROS1-tyrosine kinase inhibitors (TKIs). Commonly acquired resistance mechanisms include a second… read more here.
Keywords: met amplification; ros1 rearranged; resistance; case ... See more keywords
Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29030160
Abstract: The use, safety and effectiveness of crizotinib as part of the management of ROS1-rearranged NSCLC patients in a real-world Canadian clinical cohort was the focus of this retrospective review. Twenty-one ROS1-rearranged patients with advanced/metastatic disease… read more here.
Keywords: ros1 rearranged; crizotinib; real world; cohort ... See more keywords